中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2015年
14期
3-5
,共3页
子痫前期%早发型%孕妇%硫酸镁%低分子肝素
子癇前期%早髮型%孕婦%硫痠鎂%低分子肝素
자간전기%조발형%잉부%류산미%저분자간소
Preeclampsia%Early-onset%Pregnant woman%Magnesium sulfate%Low molecular heparin
目的:评价硫酸镁联合低分子肝素和单纯硫酸镁治疗早发型子痫前期孕妇的临床效果,探讨两种治疗方法对胎儿和新生儿的预后影响。方法86例早发型子痫前期患者按照随机数字表法分为A、B两组,每组43例。A组患者给予单纯硫酸镁进行治疗, B组患者在A组患者治疗的基础上予以低分子肝素进行治疗。对两组患者治疗前后的收缩压、24 h尿蛋白定量、并发症、胎儿(生理物理评分)和新生儿(阿氏评分、体重及并发症)的预后情况进行观察比较。结果两组患者治疗后的收缩压显著低于治疗前(P<0.05),24 h尿蛋白定量显著高于治疗前(P<0.05);治疗后B组患者的收缩压显著低于A组(P<0.05),治疗后两组胎儿的生物物理评分显著优于治疗前(P<0.05),新生儿的阿氏评分10 min显著高于1 min(P<0.05),而B组新生儿1 min和10 min的阿氏评分显著高于A组(P<0.05), B组新生儿的并发症发生率显著低于A组(25.6%VS 90.7%, P<0.01)。结论硫酸镁联合低分子肝素治疗早发型子痫前期孕妇疗效更加显著,并能显著减少孕妇的并发症发生率,对胎儿和新生儿的预后较好。
目的:評價硫痠鎂聯閤低分子肝素和單純硫痠鎂治療早髮型子癇前期孕婦的臨床效果,探討兩種治療方法對胎兒和新生兒的預後影響。方法86例早髮型子癇前期患者按照隨機數字錶法分為A、B兩組,每組43例。A組患者給予單純硫痠鎂進行治療, B組患者在A組患者治療的基礎上予以低分子肝素進行治療。對兩組患者治療前後的收縮壓、24 h尿蛋白定量、併髮癥、胎兒(生理物理評分)和新生兒(阿氏評分、體重及併髮癥)的預後情況進行觀察比較。結果兩組患者治療後的收縮壓顯著低于治療前(P<0.05),24 h尿蛋白定量顯著高于治療前(P<0.05);治療後B組患者的收縮壓顯著低于A組(P<0.05),治療後兩組胎兒的生物物理評分顯著優于治療前(P<0.05),新生兒的阿氏評分10 min顯著高于1 min(P<0.05),而B組新生兒1 min和10 min的阿氏評分顯著高于A組(P<0.05), B組新生兒的併髮癥髮生率顯著低于A組(25.6%VS 90.7%, P<0.01)。結論硫痠鎂聯閤低分子肝素治療早髮型子癇前期孕婦療效更加顯著,併能顯著減少孕婦的併髮癥髮生率,對胎兒和新生兒的預後較好。
목적:평개류산미연합저분자간소화단순류산미치료조발형자간전기잉부적림상효과,탐토량충치료방법대태인화신생인적예후영향。방법86례조발형자간전기환자안조수궤수자표법분위A、B량조,매조43례。A조환자급여단순류산미진행치료, B조환자재A조환자치료적기출상여이저분자간소진행치료。대량조환자치료전후적수축압、24 h뇨단백정량、병발증、태인(생리물리평분)화신생인(아씨평분、체중급병발증)적예후정황진행관찰비교。결과량조환자치료후적수축압현저저우치료전(P<0.05),24 h뇨단백정량현저고우치료전(P<0.05);치료후B조환자적수축압현저저우A조(P<0.05),치료후량조태인적생물물리평분현저우우치료전(P<0.05),신생인적아씨평분10 min현저고우1 min(P<0.05),이B조신생인1 min화10 min적아씨평분현저고우A조(P<0.05), B조신생인적병발증발생솔현저저우A조(25.6%VS 90.7%, P<0.01)。결론류산미연합저분자간소치료조발형자간전기잉부료효경가현저,병능현저감소잉부적병발증발생솔,대태인화신생인적예후교호。
Objective To evaluate clinical effect by magnesium sulfate combined with low molecular heparin and single magnesium sulfate in the treatment of early-onset preeclampsia, and to investigate influence of the two methods on prognosis of fetus and newborn. Methods A total of 86 early-onset preeclampsia patients were divided by random number table into group A and group B, with 43 cases in each group. The group A received single magnesium sulfate. The group B received additional low molecular heparin on the basis of treatment measures in group A. Observation and comparison were made on systolic pressure, 24 h urine protein quantitation, complications, prognosis of fetus (biological and physics scores) and newborn (Apgar score, body weight and complications) in the two groups before and after treatment. Results Both groups had much lower systolic pressure after treatment than that before treatment (P<0.05), while their 24 h urine protein quantitation was much higher than that before treatment (P<0.05). The group B and much lower systolic pressure after treatment than the group A (P<0.05). Both groups had obviously better biological and physics scores of fetus after treatment than those before treatment (P<0.05), and newborn Apgar score in 10 min was much higher than that in 1 min (P<0.05). The group B had higher newborn Apgar score in 1 min and 10 min than the group A (P<0.05). The group B also had lower incidence of newborn complications than the group A (25.6%VS 90.7%, P<0.01). Conclusion Combination of magnesium sulfate and low molecular heparin provides precise effect in treating early-onset preeclampsia, with significantly reduced incidence of complications in pregnant woman. This method is good for prognosis of fetus and newborn.